Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Avacta reports further progress in chemotherapy trial
(Sharecast News) - Avacta Group announced the successful completion of the first cohort and the start of dosing for three patients in the second cohort of the second arm in its phase one trial of AVA6000, a peptide drug conjugate form of doxorubicin chemotherapy, on Thursday. The AIM-traded company also initiated a FAPI-PET sub-study within the trial to better characterise the FAP-positive disease burden at the study entry for selected patients.
It said the phase one trial aimed to evaluate the safety and tolerability of AVA6000, leveraging Avacta's proprietary preCISION technology.
Following positive data from the first arm, arm two was designed to optimise the dosing schedule and efficacy, using a two-weekly dosing regimen.
The first cohort in the second arm was completed without any adverse safety signals, and the second cohort had started dosing, with three patients already treated.
In addition to the main trial, Avacta said it had initiated a sub-study in partnership with SOFIE, using baseline FAPI-74 PET scanning.
The sub-study aimed to better characterise whole-body tumour expression of the preCISION molecule's target and levels of fibroblast activation protein, or FAP, expression - an enzyme found in high concentrations in many solid tumours.
It said the insights from the sub-study would inform on various indications for further efficacy studies, and represent an ongoing collaboration between Avacta and SOFIE.
Avacta said it remained on track to achieve its goals for the second half of 2024, including the start of the dose expansion phase 1b efficacy study and the presentation of further data from the AVA6000 trial.
The outcomes of the expansion study would guide the selection of an optimal single indication for a subsequent phase two efficacy study.
"This is an important milestone which supports our continued confidence in AVA6000 and in the wider preCISION platform," said chief executive officer Christina Coughlin.
"The introduction of a new diagnostic approach of [18F]FAPI-74 -PET scanning into the programme will help to better characterise the FAP expression among patients, potentially assisting in indication selection.
"We're excited to be working with our investigators to integrate these tools to accelerate our efforts to optimise indications, dosing and schedule, as we bring this promising program through clinical studies."
At 1606 BST, shares in Avacta Group were up 5.25% at 43.15p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.